The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group
Open accessAbstract
Intravenously administered ciprofloxacin was compared with imipenem for the treatment of severe pneumonia. In this prospective, randomized, double-blind, multicenter trial, which included an intent-to-treat analysis, a total of 405 patients with severe pneumonia were enrolled. The mean APACHE II score was 17.6, 79% of the patients required mechanical ventilation, and 78% had nosocomial pneumonia. A subgroup of 205 patients (98 ciprofloxacin-treated patients and 107 imipenem-treated patients) were evaluable for the major efficacy endpoints. Patients were randomized to receive intravenous treatment with either ciprofloxacin (400 mg every 8 h) or imipenem (1,000 mg every 8 h), and doses were adjusted for renal function. The primary and secondary efficacy endpoints were bacteriological and clinical responses at 3 to 7 days after completion of therapy. Ciprofloxacin-treated patients had a higher bacteriological eradication rate than did imipenem-treated patients (69 versus 59%; 95% confidence interval of -0.6%, 26.2%; P = 0.069) and also a significantly higher clinical response rate (69 versus 56%; 95% confidence interval of 3.5%, 28.5%; P = 0.021). The greatest difference between ciprofloxacin and imipenem was in eradication of members of the family Enterobacteriaceae (93 versus 65%; P = 0.009). Stepwise logistic regression analysis demonstrated the following factors to be associated with bacteriological eradication: absence of Pseudomonas aeruginosa (P < 0.01), higher weight (P < 0.01), a low APACHE II score (P = 0.03), and treatment with ciprofloxacin (P = 0.04). When P. aeruginosa was recovered from initial respiratory tract cultures, failure to achieve bacteriological eradication and development of resistance during therapy were common in both treatment groups (67 and 33% for ciprofloxacin and 59 and 53% for imipenem, respectively). Seizures were observed more frequently with imipenem than with ciprofloxacin (6 versus 1%; P = 0.028). These results demonstrate that in patients with severe pneumonia, monotherapy with ciprofloxacin is at least equivalent to monotherapy with imipenem in terms of bacteriological eradication and clinical response. For both treatment groups, the presence of P. aeruginosa had a negative impact on treatment success. Seizures were more common with imipenem than with ciprofloxacin. Monotherapy for severe pneumonia is a safe and effective initial strategy but may need to be modified if P. aeruginosa is suspected or recovered from patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
APACHE II: a severity of disease classification system.
Knaus, W. A., Draper, E. S., Wagner, D. P., & Zimmerman, J. E. (1985) · PubMed · Cited by 6,034
Fagon, J.-Y., Chastre, J., Domart, Y., Trouillet, J.-L., Pierre, J., Darne, C., & Gibert, C. (1989) · American Review of Respiratory Disease · doi:10.1164/ajrccm/139.4.877 · Cited by 823
THE NATIONWIDE NOSOCOMIAL INFECTION RATE
HALEY, R. W., CULVER, D. H., WHITE, J. W., MORGAN, W. M., & EMORI, T. G. (1985) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113988 · Cited by 701
Celis, R., Torres, A., Gatell, J. M., Almela, M., Rodríguez-Roisin, R., & Agustí-Vidal, A. (1988) · Chest · doi:10.1378/chest.93.2.318 · Cited by 683
Risk factors for pneumonia and fatality in patients receiving continuous mechanical ventilation.
Craven, D. E., Kunches, L. M., Kilinsky, V., Lichtenberg, D. A., Make, B. J., & McCabe, W. R. (1986) · PubMed · Cited by 676
Fluoroquinolone antimicrobial agents
Wolfson, J. S., & Hooper, D. C. (1989) · Clinical Microbiology Reviews · doi:10.1128/cmr.2.4.378 · Cited by 649
Severe Community-acquired Pneumonia: Epidemiology and Prognostic Factors
Torres, A., Serra-Batlles, J., Ferrer, A., Jiménez, P., Celis, R., Cobo, E., & Rodriguez-Roisin, R. (1991) · American Review of Respiratory Disease · doi:10.1164/ajrccm/144.2.312 · Cited by 613
Hilf, M., Yu, V. L., Sharp, J., Zuravleff, J. J., Korvick, J. A., & Muder, R. R. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90695-5 · Cited by 563
Fagon, J.-Y., Chastre, J., Hance, A. J., Guiguet, M., Trouillet, J.-L., Domart, Y., Pierre, J., & Gibert, C. (1988) · American Review of Respiratory Disease · doi:10.1164/ajrccm/138.1.110 · Cited by 426
LEU, H.-S., KAISER, D. L., MORI, M., WOOLSON, R. F., & WENZEL, R. P. (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115245 · Cited by 417
Chastre, J. E., Viau, F., Brun, P., Pierre, J., Dauge, M., Bouchama, A., Akesbi, A., & Gibert, C. (1984) · PubMed · doi:10.1164/arrd.1984.130.5.924 · Cited by 355
The Radiologic Diagnosis of Autopsyproven Ventilator-associated Pneumonia
Wunderink, R. G., Woldenberg, L. S., Zeiss, J., Day, C. M., Ciemins, J., & Lacher, D. A. (1992) · Chest · doi:10.1378/chest.101.2.458 · Cited by 332
Self-citationThe analysis of several 2× 2 contingency tables
ZELEN, M. (1971) · Biometrika · doi:10.1093/biomet/58.1.129 · Cited by 261
Torres, A., De La Bellacasa, J. P., Xaubet, A., Gonzalez, J., Rodríguez-Roisin, R., De Anta, M. T. J., & Vidal, A. A. (1989) · American Review of Respiratory Disease · doi:10.1164/ajrccm/140.2.306 · Cited by 258
Respiratory Infection Complicating Long-term Tracheostomy
Niederman, M. S., Ferranti, R. D., Zeigler, A., Merrill, W. W., & Reynolds, H. Y. (1984) · Chest · doi:10.1378/chest.85.1.39 · Cited by 191
Self-citationEffect of intensive care unit nosomial pneumonia on duration of stay and mortality
Craig, C. P., & Connelly, S. (1984) · American Journal of Infection Control · doi:10.1016/0196-6553(84)90114-7 · Cited by 176
Peloquin, C. A. (1989) · Archives of Internal Medicine · doi:10.1001/archinte.1989.00390100083020 · Cited by 167
Neu, H. C., & Labthavikul, P. (1982) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.21.1.180 · Cited by 152
Torres, A., de la Bellacasa, J. P., Rodriguez‐Roisin, R., de Anta, M. T. J., & Agustí-Vidal, A. (1988) · American Review of Respiratory Disease · doi:10.1164/ajrccm/138.1.117 · Cited by 151
Caekenberghe, D. L. V., & Pattyn, S. R. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.25.4.518 · Cited by 125
Cook, D. J., FitzGerald, J. M., Guyatt, G. H., & Walter, S. (1991) · Journal of Intensive Care Medicine · doi:10.1177/088506669100600405 · Cited by 56
Guerrero, M. F., Arnau, C., Valdés, L., Vallvé, C., Gudiol, F., & Rodríguez-Torres, A. (1991) · Infection · doi:10.1007/bf01715772 · Cited by 30
Cefoperazone versus ceftriaxone monotherapy of nosocomial pneumonia
Mangi, R. J., Peccerillo, K., Ryan, J. L., et al. (1992) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(92)90086-9 · Cited by 28
Hartenauer, U. (1990) · Journal of Hospital Infection · doi:10.1016/0195-6701(90)90081-x · Cited by 25
Pneumonia in the Intensive Care Unit Setting
Gleeson, K., & Reynolds, H. Y. (1992) · Journal of Intensive Care Medicine · doi:10.1177/088506669200700104 · Cited by 6
Cited by
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Ventilator-associated Pneumonia
Chastre, J., & Fagon, J.-Y. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.7.2105078 · Cited by 2,812
Niederman, M. S., Mandell, L. A., Anzueto, A., Bass, J. B., Broughton, W. A., Campbell, G. D., Dean, N., File, T., Fine, M. J., Gross, P. A., et al. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.7.at1010 · Cited by 2,150
Self-citationStenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Brooke, J. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-11 · Cited by 1,434
Metadata
- Authors
- Fink, M. P., Snydman, D. R., Niederman, M. S., Leeper, K. V., Johnson, R. H., Heard, S. O., Wunderink, R. G., Caldwell, J. W., Schentag, J. J., & Siami, G. A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1994-03
- Volume
- 38
- Issue
- 3
- Pages
- 547-557
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2004449157
- Cited by
- 461
- References
- 27
- FWCI
- 23.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.